Compare Novartis AG (NVS) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novartis AG vs Omnicom Group Inc. — how do they compare? Novartis AG trades at $152.51 (market cap $295.37B), while Omnicom Group Inc. trades at $85.39 (market cap $23.58B). The key difference: Novartis AG is far larger — about 12.5× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals.
| NVS | OMC | |
|---|---|---|
Market Cap | $295.37B | $23.58B |
Sector | Health | Media |
52-Week High | $168.62 | $86.22 |
52-Week Low | $119.31 | $67.27 |
Enterprise Value | $336.69B | $31.66B |
Dividend Yield | 3.07% | 3.72% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novartis AG (NVS) trades at $152.54, down 2.71% on the day, with a neutral technical signal. The company reported strong Q2 2026 earnings, beating EPS estimates of $2.17 with $2.41 actual, driven by oncology drug performance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%. Analyst consensus is mixed with 24% buy, 68% hold, and 8% sell ratings among 25 analysts.
The outlook is cautiously optimistic, supported by a robust drug pipeline and recent earnings strength, but risks include generic competition pressure on key drugs like Entresto and rising debt levels. The stock presents a stable investment opportunity with solid profitability, though growth may be tempered by industry headwinds.
Omnicom Group (OMC) trades at $85.34, up 0.82% today, with a bullish technical signal from moving averages and a consensus price target of $107.00. Recent Q2 2026 earnings beat expectations with $2.65 EPS and 6.1% organic revenue growth, though net income margin remains thin at 1.74%. The company shows strong cash flow from operations at $2.94 billion in 2025 and pays a $0.80 quarterly dividend.
Outlook is positive with post-merger synergies driving margin expansion, but high P/E of 232.3 and integration risks from the Interpublic acquisition pose challenges. Analyst sentiment is mixed with 32% buy ratings, highlighting value potential amid execution concerns. Key catalysts include sustained organic growth and cost savings realization.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
